Fundz

Crispr Therapeutics Names Sivakesava Sakhamuri Chief Technical Officer

PUBLIC · CRSPNov 03, 2026
From SEC Form 3

Position

Chief Technical Officer

Company

Crispr Therapeutics

Sivakesava Sakhamuri
ZugBiotechnologyHealthcareHealth CareGeneticsTherapeutics

Description

Sivakesava Sakhamuri became Chief Technical Officer of Crispr Therapeutics on November 2, 2026, per the SEC Form 3 filed November 2, 2026. A Form 3 is the first ownership report a new officer files, due within 10 days of taking the role.

Who to call at Crispr Therapeutics, and when

A new leader at Crispr Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Crispr Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Crispr Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Crispr Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Crispr Therapeutics

Location

Zug, Zug, Switzerland

About

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Crispr Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Phuong
Likely contact at this company
••••••••@••••••••

See Phuong's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Crispr Therapeutics's next move

Learn about Strategic plan

Crispr Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.